Siqing Fu - Concepedia

Author

Siqing Fu

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Brady, P, Fu Siqing, James R. Tonra, S Fu, S Q Fu, S. FU, S. Fu, S. Q. Fu, S.Q. FU, S.Q. Fu

922

Publications

14.8K

Citations

H-Index

113

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center University of California San Diego Sarah Cannon Moores Cancer Center HealthONE

About

Siqing Fu is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	85	4.6K
2	Health Sciences	18	24	734
3	Engineering	4	4	653
4	Allergy	2	2	43
5	Biochemistry	1	1	335

Siqing Fu

216

Publications

13.2K

Citations

H-Index

Page 1

	Year	Citations
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative Apostolia M. Tsimberidou, Nancy G. Iskander, David S. Hong, Clinical Cancer Research	2012	528
Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML AB Deisseroth, Z. Zu, David F. Claxton, Blood	1994	484
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations Filip Jankú, Jennifer J. Wheler, Shannon N. Westin, Journal of Clinical Oncology	2012	447
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials Timothy A. Yap, Naval Daver, Mikhila Mahendra, Nature Medicine Hematological MalignancyOncologyBiochemistryMedicineAcute Myeloid Leukemia	2023	335
<i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors Filip Jankú, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, Molecular Cancer Therapeutics Tumor BiologyAdvanced CancersMedicineCancer Cell BiologyPathology	2011	328
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells Chad Tang, James W. Welsh, Patricia M. de Groot, Clinical Cancer Research	2016	309
<i>PIK3CA</i> Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials Filip Jankú, Jennifer J. Wheler, Aung Naing, Cancer Research EngineeringGeneticsPathologyTumor BiologySignaling Pathway	2012	295
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study Jennifer J. Wheler, Filip Jankú, Aung Naing, Cancer Research EngineeringPathologyCancer RegistrationTumor BiologyTumor Heterogeneity	2016	232
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial Panagiotis A. Konstantinopoulos, Su-Chun Cheng, Andrea E. Wahner Hendrickson, The Lancet Oncology MedicineGemcitabine Versus GemcitabineMetronomic TherapyGynecologyCancer Treatment	2020	227
Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors Filip Jankú, David S. Hong, Siqing Fu, Cell Reports Pten AbnormalitiesPten AberrationPathologyPharmacotherapyCancer Biology	2014	226

Page 1